Abstract 13144: MicroRNA Sequencing Highlights Regulatory Networks Upstream of Osteopontin and B-type Natriuretic Peptide in Acute Coronary Sydrome
Introduction: The genomic regulatory networks underlying the pathogenesis of acute coronary syndrome (ACS) are incompletely understood. As intermediate traits, circulating protein biomarkers report on underlying disease severity and are powerfully prognostic in ACS. We hypothesized that integration of dense microRNA (miRNA) profiling with measurement of biomarkers would highlight potential regulatory pathways.
Methods: We studied 186 patients enrolled in the biomarker substudy of the TRILOGY clinical trial of ACS. MiRNA sequencing was performed on RNA extracted from whole blood, and seven known prognostic protein biomarkers were measured from plasma (N-terminal pro B-type natriuretic peptide [NT-proBNP], C-reactive protein, osteopontin [OPN], myeloperoxidase, growth differentiation factor 15, monocyte chemoattractant protein 1, and neopterin). MiRNAs were tested for association with these biomarkers using generalized linear models. Target genes putatively regulated by the associated miRNAs were examined using pathway analysis.
Results: Fourteen miRNAs, including cardiac-related miRs 20b-5p and 320a,b and d, were associated with OPN levels (min. p=1.1x10-4), and five miRNAs, including cardiac-related miRs 25-3p and 423-3p, were associated with NT-proBNP levels (min. p=3.4x10-4); no other biomarkers showed significant associations. Sixty-three KEGG pathways were enriched in the target genes of either NT-proBNP- or OPN-associated miRNAs, with five pathways found in the top ten for both biomarkers: prion diseases, fatty acid biosynthesis, lysine degradation, protein processing in endoplasmic reticulum, and viral carcinogenesis.
Conclusions: By integrating large-scale microRNA profiling with circulating biomarkers as intermediate traits, we identified associations of known cardiac-related and novel miRs with two prognostic biomarkers (OPN and NT-proBNP), and identified potential genomic regulatory networks underlying these biomarkers. We further identified novel non-cardiac genomic pathways associated with these biomarkers. These results may inform future studies delineating genomic pathways underlying ACS outcomes.
Author Disclosures: L.C. Kwee: None. E. Grass: None. M.L. Neely: None. S.G. Gregory: Consultant/Advisory Board; Modest; Pfizer. J.V. Haas: Employment; Significant; Eli Lilly. D.A. Laska: Employment; Significant; Eli Lilly. M. Kowala: Employment; Significant; Eli Lilly. L.F. Michael: Employment; Significant; Eli Lilly. J.R. Wetterau: Employment; Significant; Eli Lilly. K.L. Duffin: Employment; Significant; Eli Lilly. M. Roe: Research Grant; Significant; AstraZeneca, Eli Lilly & Co., Janssen Pharmaceuticals, Sanofi-Aventis, Daiichi-Sankyo, Familial Hypercholesterolemia Foundation, Ferring Pharmaceuticals. Consultant/Advisory Board; Modest; Eli Lilly & Co, Daiichi-Sankyo, Elsevier Publishers, Boehringer-Ingelheim, PriMed, Myokardia. Other; Modest; Amgen, Bristol-Myers Squibb. E.M. Ohman: Research Grant; Significant; Daiichi Sankyo, Gilead Sciences, Janssen Pharmaceuticals. Consultant/Advisory Board; Modest; Abbott Vascular, Medscape, AstraZeneca, Biotie, Boehringer Ingelheim, Daiichi Sankyo, Merck, St. Jude Medical, Stealth Peptides, The Medidines Company. Consultant/Advisory Board; Significant; Faculty Connection, Abiomed. K.A. Fox: Research Grant; Modest; Lilly, Bayer, Johnson-Johnson, AstraZeneca. Speakers Bureau; Modest; Bayer, Johnson-Johnson, AstraZeneca, Sanofi-Aventis. Consultant/Advisory Board; Modest; Lilly, Bayer, Johnson-Johnson, AstraZeneca, Sanofi-Aventis, Boehringer Ingelheim, Eli Lilly. H. White: Research Grant; Significant; Sanofi, Eli Lilly, MSD. Honoraria; Modest; Astra Zeneca. P. Armstrong: Research Grant; Significant; Merck, AstraZeneca. Consultant/Advisory Board; Modest; Merck. Other; Modest; Merck. M.Y. Chan: Research Grant; Significant; Eli-Lilly, Astra-Zeneca, Bayer Healthcare. Speakers Bureau; Modest; Astra Zeneca. S.H. Shah: None.
- © 2016 by American Heart Association, Inc.